Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma

Br J Radiol. 2006 May;79(941):365-7. doi: 10.1259/bjr/31368041.

Authors

A Guermazi¹, M E Juweid

Affiliation

¹ Synarc Inc. and University of California, San Francisco, CA 94105, USA.

PMID: 16632614
DOI: 10.1259/bjr/31368041

No abstract available

MeSH terms

Fluorodeoxyglucose F18
Gallium Radioisotopes
Humans
Lymphoma, Non-Hodgkin / diagnostic imaging*
Lymphoma, Non-Hodgkin / therapy
Magnetic Resonance Imaging
Neoplasm Staging
Neoplasm, Residual / diagnostic imaging*
Neoplasm, Residual / therapy
Positron-Emission Tomography*
Practice Guidelines as Topic
Predictive Value of Tests
Radiopharmaceuticals
Tomography, X-Ray Computed
Treatment Outcome

Substances

Gallium Radioisotopes
Radiopharmaceuticals
Fluorodeoxyglucose F18